Newsfeeds - Spark Newswire

1 minute read

FDA
News

Seagen Announces U.S. FDA Approval Of New Indication For Adcetris For Children With Previously Untreated High Risk Hodgkin Lymphoma

Today, 6:15 PM

– Approval Based on Phase 3 Clinical Study That Demonstrated a 59% Reduction in Risk of Disease Progression or Relapse, Second Malignancy or Death vs. Standard of Care –

SGEN

1 minute read

JMP Securities Maintains Market Outperform on Seagen, Lowers Price Target to $142

By Benzinga Newsdesk

Today, 6:15 PM

JMP Securities analyst Reni Benjamin maintains Seagen (NASDAQ:SGEN) with a Market Outperform and lowers the price target from $196 to $142.

SGEN

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 6:15 PM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

1 minute read

CNBC Halftime Report Final Trades: Seagen, Honeywell International, XPO Logistics & New York Community Bancorp

By Benzinga Newsdesk

Today, 6:15 PM

- CNBC

HON

1 minute read

Barclays Maintains Equal-Weight on Seagen, Lowers Price Target to $136

By Benzinga Newsdesk

Today, 6:15 PM

Barclays analyst Gena Wang maintains Seagen (NASDAQ:SGEN) with a Equal-Weight and lowers the price target from $174 to $136.

SGEN

1 minute read

Morgan Stanley Maintains Overweight on Seagen, Raises Price Target to $171

By Benzinga Newsdesk

Today, 6:15 PM

Morgan Stanley analyst Matthew Harrison maintains Seagen (NASDAQ:SGEN) with a Overweight and raises the price target from $170 to $171.

SGEN

18 minute read

Earnings

Earnings Scheduled For October 27, 2022

By Benzinga Insights

Today, 6:15 PM

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

AAPL

1 minute read

Analyst Ratings

What 9 Analyst Ratings Have To Say About Seagen

By Benzinga Insights

Today, 6:15 PM

Over the past 3 months, 9 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

SGEN

2 minute read

A Bearish Sign Appears On Seagen’s Chart

By Benzinga Insights

Today, 6:15 PM

If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

SGEN

2 minute read

Analyst Ratings

Morgan Stanley Maintains Overweight Rating for Seagen: Here’s What You Need To Know

By Benzinga Insights

Today, 6:15 PM

Morgan Stanley has decided to maintain its Overweight rating of Seagen (NASDAQ:SGEN) and lower its price target from $181.00 to $170.00. Shares of Seagen are trading up 0.36% over the last 24 hours, at $133.78 per share. A move to $170.00 would account for a 27.08% increase from the current share price.

SGEN